Sofosbuvir Daclatasvir

Daclatasvir + Sofosbuvir plan official its effective treatment rates higher, so the Sofosbuvir + ledipasvir or Sofosbuvir coalition after the RIBAVIRIN or interferon, patients and a better choice. Actually Daclatasvir without FDA pre-market has been widely accepted among patients, because it has been approved in the eu and Japan and other countries and curative effect is very good. So that some southeast Asian generic drug companies compete to generic, such as Bangladesh, Laos has in generic card he wei, after India, gradually attracted the attention of hepatitis c patients from all over the world.
In fact, the best treatment plan is: Daclatasvir + Sofosbuvir, but from economic considerations, usually use Sofosbuvir plus RIBAVIRIN in suggest that type 2. Type we use Sofosbuvir + ledipasvir from economic considerations, it is also dedicated to research and development of type 1, at present, India have been listed, for three and six model, I'm afraid it is better to choose the combination of Daclatasvir + Sofosbuvir the safest, of course, if the economy allows, other classification is also the best with it.
Daclatasvir is indicated for use, with sofosbuvir, with or without ribavirin for the treatment of patients with chronic HCV genotype 1 or 3. The use of ribavirin depends on the patient population treated as outlined below. For patients with HCV/HIV-1 coinfection, the dosage and duration are the same as listed below.

Genotype 1

  • Genotype 1, without cirrhosis: daclatasvir plus sofosbuvir for 12 weeks
  • Genotype 1, compensated (Child-Pugh A) cirrhosis*: daclatasvir plus sofosbuvir for 12 weeks
  • Genotype 1, decompensated (Child-Pugh B or C) cirrhosis*^: daclatasvir plus sofosbuvir plus ribavirin for 12 weeks
  • Genotype 1, post-transplant: daclatasvir plus sofosbuvir plus ribavirin for 12 weeks

*For patients with genotype 1a and cirrhosis, consider screening for the presence of baseline NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93 prior to initiating treatment.

^For HCV genotype 1 patients with Child-Pugh C cirrhosis, the optimal duration of therapy with daclatasvir plus sofosbuvir plus ribavirin has not been established

Genotype 3

  • Genotype 3, without cirrhosis: daclatasvir plus sofosbuvir for 12 weeks
  • Genotype 3, compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis: daclatasvir plus sofosbuvir plus ribavirin for 12 weeks
  • Genotype 3, post-transplant: daclatasvir plus sofosbuvir plus ribavirin for 12 weeks

#For HCV genotype 3 patients with cirrhosis the optimal duration of therapy with daclatasvir plus sofosbuvir, with or without ribavirin, has not been established.

NOTE: For the use of dasabuvir and sofosbuvir in genotype 3 patients with cirrhosis, the AASLD/IDSA guidance recommends 24 weeks of therapy, with or without ribavirin.

Registration hotline: (001)4152318413